Abstract
Chronic hepatitis C and B are well-recognized and potentially preventable risk factors for hepatocellular carcinoma (HCC) development. Clinical and epidemiological studies suggest that therapy with interferon-α may reduce the overall risk of HCC development in patients with chronic hepatitis C, who achieve sustained virological response, but even in those who fail to eradicate the infection. In chronic hepatitis B, interferon therapy reduces the risk of HCC development in HBeAg-positive and cirrhotic patients who achieve persistent suppression of viral replication, while in HBeAg-negative patients the beneficial effect of interferon-α is not definitively confirmed. The preventive role of interferon-α after potentially curative treatment for HCC in both chronic hepatitis B and C is uncertain due to methodological flaws of the existing studies and prospective randomized controlled trials with pegylated interferon-α are needed to clarify this issue.
| Original language | English |
|---|---|
| Pages (from-to) | 455-464 |
| Number of pages | 10 |
| Journal | Gastroenterologie Clinique et Biologique |
| Volume | 35 |
| Issue number | 6-7 |
| DOIs | |
| Publication status | Published - 2011 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
Cite this
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? / Vezali, Elena; Aghemo, Alessio; Lampertico, Pietro; Colombo, Massimo.
In: Gastroenterologie Clinique et Biologique, Vol. 35, No. 6-7, 2011, p. 455-464.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?
AU - Vezali, Elena
AU - Aghemo, Alessio
AU - Lampertico, Pietro
AU - Colombo, Massimo
PY - 2011
Y1 - 2011
N2 - Chronic hepatitis C and B are well-recognized and potentially preventable risk factors for hepatocellular carcinoma (HCC) development. Clinical and epidemiological studies suggest that therapy with interferon-α may reduce the overall risk of HCC development in patients with chronic hepatitis C, who achieve sustained virological response, but even in those who fail to eradicate the infection. In chronic hepatitis B, interferon therapy reduces the risk of HCC development in HBeAg-positive and cirrhotic patients who achieve persistent suppression of viral replication, while in HBeAg-negative patients the beneficial effect of interferon-α is not definitively confirmed. The preventive role of interferon-α after potentially curative treatment for HCC in both chronic hepatitis B and C is uncertain due to methodological flaws of the existing studies and prospective randomized controlled trials with pegylated interferon-α are needed to clarify this issue.
AB - Chronic hepatitis C and B are well-recognized and potentially preventable risk factors for hepatocellular carcinoma (HCC) development. Clinical and epidemiological studies suggest that therapy with interferon-α may reduce the overall risk of HCC development in patients with chronic hepatitis C, who achieve sustained virological response, but even in those who fail to eradicate the infection. In chronic hepatitis B, interferon therapy reduces the risk of HCC development in HBeAg-positive and cirrhotic patients who achieve persistent suppression of viral replication, while in HBeAg-negative patients the beneficial effect of interferon-α is not definitively confirmed. The preventive role of interferon-α after potentially curative treatment for HCC in both chronic hepatitis B and C is uncertain due to methodological flaws of the existing studies and prospective randomized controlled trials with pegylated interferon-α are needed to clarify this issue.
UR - http://www.scopus.com/inward/record.url?scp=80052309181&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052309181&partnerID=8YFLogxK
U2 - 10.1016/j.clinre.2011.02.008
DO - 10.1016/j.clinre.2011.02.008
M3 - Article
C2 - 21435968
AN - SCOPUS:80052309181
VL - 35
SP - 455
EP - 464
JO - Clinics and Research in Hepatology and Gastroenterology
JF - Clinics and Research in Hepatology and Gastroenterology
SN - 2210-7401
IS - 6-7
ER -